key: cord-1030730-0kkaw04x
authors: Colson, Philippe; La Scola, Bernard; Lagier, Jean-Christophe; Gautret, Philippe; Raoult, Didier
title: Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19
date: 2021-01-04
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106238
sha: 8859cf90fd709ff2ec84ba49c78ef03a8a99b2cc
doc_id: 1030730
cord_uid: 0kkaw04x

nan

. The fact that our paper had such an impact (more than 2,500 citations in Google Scholar) testifies that it met an important expectation. In order to be able to give an element of reflection for COVID-19 therapeutics, we have chosen as endpoint the viral clearance assessed by PCR in the nasopharynx. Indeed, this marker has become necessary for the management of bacterial and viral infections, as in the cases of HIV infection or hepatitis C. Chinese authors reported in March 2020 that the median duration of viral carriage in the nasopharynx was 20 days and that the longest carriage lasted 37 days [3] . Hence, we initially submitted a project that included the analysis of a single arm, using hydroxychloroquine (HCQ), to determine if we could have a shortening of the duration of viral carriage in our patients compared to this Chinese work. Fortunately, we had to test and follow up patients who had been hospitalized in other centers and who did not receive this treatment, which allowed comparison. The results were interpreted by the laboratories that performed the tests. In our laboratory, PCR were determined to be positive in case of Ct values lower than 35, which we were able to confirm in the largest study published to date that compared culture and PCR [4] . Since then, we have performed > 250,0 0 0 PCRs in our laboratory, diagnosed > 13,0 0 0 people, and the efficacy of HCQ on viral carriage, which was the only element we reported in our seminal article, has been confirmed in a larger set of patients by our team [5] as well as by others [6] . Studies and meta-analyses are consistent regarding the fact that this treatment shortens the duration of viral carriage. Finally, the importance of this preliminary paper was underlined by the fact that numerous international publications have now been produced on HCQ that evaluated its effect, either on virus disappearance or on death. In total, it is important to keep in mind that during emerging epidemics with unknown viruses, preliminary data are essential to allow the choice of therapeutic strategies when no treatment has been validated. The need for information in real-time in such context is also illustrated by the burst of pre-print publications during this SARS-CoV-2 pandemic.

The authors declare no competing interests. 

Not applicable.

HCQ): real treatment or false hope?

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis

Raoult D Response to IJAA-D-20-00393. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis

Didier Raoult * IHU-Méditerranée Infection